Læknaneminn - 01.10.1995, Side 46

BLOÐÞYNNING
50.Raschke RA, Reilly BM, Guidtry JR, Fontana JR,
Srinivas S. A weight based nomogram compared with a
‘standard care’ nomogram. Ann Intern Med.
1993; 119:874-881.
51 .Rihal CS, Flather M, Hirsh J, Yusuf S. Advances in
antithrombotic drug therapy for coronary artery disease.
European Heart Journal 1995; 16 (Supplement D); 10-21.
52.Roth GJ, Calverley DC. Aspirin, platelets, and
thrombosis: Theory and practice. Blood 1994;83:885-98.
53.Salzman EW, Hirsh J, Marder VJ. Clinical use of
heparin. í: Colman RW, Hirsh J, Marder VJ, Salzman JB,
ritstj. Hemostasis and Thrombosis: Basic Principles and
Clinical Practice 3. útg. Philadelphia: J.B. Lippincott,
1994: 1584-91.
54.Schulman S, Rhedin AS, Lindmarker P, Carlsson A,
Lárfars G, Nicol P et al. A comparison of six weeks with
six months of oral anticoagulant therapy after a first
episode of venous thromboembolism. N Engl J Med
1995;332:1661-5.
55.Serruys PW, Herrman JPR, Simon R, Rutsch W. Bode
C, Laarman GJ et al. A comparison of hirudin with
heparin in the prevention of restenosis after coronary
angioplasty. N Engl J Med 1995;333:757-63.
56.Statens legemiddelkontroll og Lákemedelsverket.
Workshop. Treatment of venous thrombosis and
pulmonary embolism, recommendations. 1995.
57.Stein PD. Acute pulmonary embolism. Disease a month
1994:471-523.
58.Stroke prevention in atrial fibrillation investigators.
Warfarin versus aspirin for prevention of
thromboembolism in atrial fibrillation: Stroke Prevention
in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
59.Suttie JW. Vitamin K Antagonists. í: Colman RW, Hirsh
J, Marder VJ, Salzman JB, ritstj. Hemostasis and
Thrombosis: Basic Principles and Clinical Practice 3.
útg. Philadelphia: J.B. Lippincott, 1994: 1562-67.
60.The European Atrial Fibrillation Trial Study Group.
Optimal oral anticoagulant therapy in patients with
nonrheumatic atrial fibrillation and recent cerebral
ischemia. N Engl J Med. 1995;333:5-10.
ól.Ukani ZA, Ezekowitz MD. Contemporary management
of atrial fibrillation. Med Clin North Am 1995;79:1135-
52.
62. Valk HW, Banga JD, Wester JWJ. Brouwer CB, Hessen
MWJ, Meuwissen OJAT. Comparing subcutaneous
danaparoid with intravenous unfractionated heparin for
the treatment of venous thromboembolism. Ann Intern
Med 1995;123:1-9.
63. Warkentin ET, Levine MN. Hirsh J, Horsewood P,
Roberts RS, Tecli M et al. Heparin induced
thrombocytopenia in patients treated with Low
molecular weight heparin or unfractioned heparin. N
Engl J Med 1995;332:1330-35.
64. Weinmann EE, Salzman EW. Deep vein thrombosis. N
Engl J Med 1994;331:1630-42.
65. White RH, McKittrick T, Hutchinson R, Twitchell J.
Temporary Discontinuation of Warfarin: Changes in the
International Normalized Ratio. Ann Intern Med.
1995;122:40-42.
66. Wolf H. Low-molecular weight heparin. Med Clin North
Am 1994;78:733-43.
67. Önundarson PT. Segavarnir á skurðdeildum.
Læknablaðið 1994;80:285-91.
68. Önundarson PT. Blóðflögufæð og segamyndun vegna
heparíns. Yfirlitsgrein. Læknablaðið 1991;77:277-84.
36
LÆKNANEMINN 2. tbl. 1995 48. árg.